wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Captain Jack who wrote (749)	5/18/1999 9:33:00 AM
From: Anthony Wong	Read Replies (1) of 942

The updated version of the Sankyo and Warner-Lambert diabetes drug development deal: Sankyo, Warner-Lambert to develop diabetes drug TOKYO, May 18 (Reuters) - Japanese drug maker Sankyo Co Ltd said on Tuesday it and Warner-Lambert Co (NYSE:WLA - news) of the United States have agreed to jointly develop a diabetes drug. Sankyo said in a statement the new drug will be an improved version of an existing diabetes treatment called troglitazone. The latter was jointly developed by Sankyo and Warner-Lambert and introduced to the Japanese and U.S. markets in March 1997. The two companies will start clinical trials on the new version of troglitazone before the end of this year. It is expected to be more effective in treating diabetes patients with serious symptoms, Sankyo said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next